Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 8, Issue , 2017, Pages 139-146

  van Wijk, Nick ^a   Slot, Rosalinde E R ^b   Duits, Flora H ^b   Strik, Marieke ^b   Biesheuvel, Egbert ^a   Sijben, John W C ^a   Blankenstein, Marinus A ^b   Bierau, Jörgen ^c   van der Flier, Wiesje M ^b   Scheltens, Philip ^b   Teunissen, Charlotte E ^b  

^a DANONE NUTRICIA RESEARCH   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Blood; Cerebrospinal fluid; Choline; Folate; Homocysteine; Mild cognitive impairment; Nutritional status; Phospholipid precursors; Uridine

Indexed keywords

ALBUMIN; BETAINE; BILIRUBIN; BIOLOGICAL MARKER; CHOLINE; FOLIC ACID; HOMOCYSTEINE; URIDINE;

AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD BRAIN BARRIER; BLOOD LEVEL; BLOOD SAMPLING; CEREBROSPINAL FLUID LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; MILD COGNITIVE IMPAIRMENT; NUTRITIONAL REQUIREMENT; PHOSPHOLIPID SYNTHESIS;

EID: 85020804800     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2017.04.005     Document Type: Article

References (50)

1. Eckert, G.P., Wood, W.G., Muller, W.E., Lipid membranes and beta-amyloid: a harmful connection. Curr Protein Pept Sci 11 (2010), 319–325.
2. Selkoe, D.J., Alzheimer's disease is a synaptic failure. Science 298 (2002), 789–791.
3. de Wilde, M.C., Overk, C.R., Sijben, J.W., Masliah, E., Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement 12 (2016), 633–644.
4. Reitz, C., Mayeux, R., Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88 (2014), 640–651.
5. Scarmeas, N., Luchsinger, J.A., Schupf, N., Brickman, A.M., Cosentino, S., Tang, M.X., et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 302 (2009), 627–637.
6. Bourre, J.M., Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging 10 (2006), 377–385.
7. Mi, W., van Wijk, N., Cansev, M., Sijben, J.W., Kamphuis, P.J., Nutritional approaches in the risk reduction and management of Alzheimer's disease. Nutrition 29 (2013), 1080–1089.
8. Gustafson, D.R., Clare Morris, M., Scarmeas, N., Shah, R.C., Sijben, J., Yaffe, K., et al. New perspectives on Alzheimer's disease and nutrition. J Alzheimers Dis 46 (2015), 1111–1127.
9. Wurtman, R.J., Cansev, M., Sakamoto, T., Ulus, I.H., Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 29 (2009), 59–87.
10. van Wijk, N., Broersen, L.M., de Wilde, M.C., Hageman, R.J., Groenendijk, M., Sijben, J.W., et al. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. J Alzheimers Dis 38 (2014), 459–479.
11. Lopes da Silva, S., Vellas, B., Elemans, S., Luchsinger, J., Kamphuis, P., Yaffe, K., et al. Plasma nutrient status of patients with Alzheimer's disease: systematic review and meta-analysis. Alzheimers Dement 10 (2014), 485–502.
12. Olde Rikkert, M.G., Verhey, F.R., Sijben, J.W., Bouwman, F.H., Dautzenberg, P.L., Lansink, M., et al. Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. J Alzheimers Dis 41 (2014), 261–271.
13. Blass, J.P., Hanin, I., Barclay, L., Kopp, U., Reding, M.J., Red blood cell abnormalities in Alzheimer disease. J Am Geriatr Soc 33 (1985), 401–405.
14. van der Flier, W.M., Pijnenburg, Y.A., Prins, N., Lemstra, A.W., Bouwman, F.H., Teunissen, C.E., et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis 41 (2014), 313–327.
15. Teunissen, C.E., Petzold, A., Bennett, J.L., Berven, F.S., Brundin, L., Comabella, M., et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73 (2009), 1914–1922.
16. Mulder, C., Verwey, N.A., van der Flier, W.M., Bouwman, F.H., Kok, A., van Elk, E.J., et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56 (2010), 248–253.
17. Imbard, A., Smulders, Y.M., Barto, R., Smith, D.E., Kok, R.M., Jakobs, C., et al. Plasma choline and betaine correlate with serum folate, plasma S-adenosyl-methionine and S-adenosyl-homocysteine in healthy volunteers. Clin Chem Lab Med 51 (2013), 683–692.
18. Smith, D.E., Hornstra, J.M., Kok, R.M., Blom, H.J., Smulders, Y.M., Folic acid supplementation does not reduce intracellular homocysteine, and may disturb intracellular one-carbon metabolism. Clin Chem Lab Med 51 (2013), 1643–1650.
19. Prasad, M.R., Lovell, M.A., Yatin, M., Dhillon, H., Markesbery, W.R., Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23 (1998), 81–88.
20. Nitsch, R.M., Blusztajn, J.K., Pittas, A.G., Slack, B.E., Growdon, J.H., Wurtman, R.J., Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 89 (1992), 1671–1675.
21. Soininen, H., Visser, P., Kivipelto, M., Hartmann, T., Grp, L.S., A clinical trial investigating the effects of Fortasyn Connect (Souvenaid) in prodromal Alzheimer's disease: results of the Lipididiet Study. Neurobiol Aging, 39, 2016, S23.
22. Cummings, J., Scheltens, P., McKeith, I., Blesa, R., Harrison, J.E., Bertolucci, P.H., et al. Effect size analyses of Souvenaid in patients with Alzheimer's disease. J Alzheimers Dis 55 (2017), 1131–1139.
23. Wang, G., Zhou, Y., Huang, F.J., Tang, H.D., Xu, X.H., Liu, J.J., et al. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. J Proteome Res 13 (2014), 2649–2658.
24. Czech, C., Berndt, P., Busch, K., Schmitz, O., Wiemer, J., Most, V., et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One, 7, 2012, e31501.
25. Ibanez, C., Simo, C., Barupal, D.K., Fiehn, O., Kivipelto, M., Cedazo-Minguez, A., et al. A new metabolomic workflow for early detection of Alzheimer's disease. J Chromatogr A 1302 (2013), 65–71.
26. Miller, B.L., Read, S., Tang, C., Jenden, D., Differences in red blood cell choline and lipid-bound choline between patients with Alzheimer disease and control subjects. Neurobiol Aging 12 (1991), 61–64.
27. Kanof, P.D., Greenwald, B.S., Mohs, R.C., Davis, K.L., Red blood cell choline. II: Kinetics in Alzheimer's disease. Biol Psychiatry 20 (1985), 375–383.
28. Walter, A., Korth, U., Hilgert, M., Hartmann, J., Weichel, O., Hilgert, M., et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 25 (2004), 1299–1303.
29. Elble, R., Giacobini, E., Higgins, C., Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 10 (1989), 45–50.
30. Jia, J.P., Jia, J.M., Zhou, W.D., Xu, M., Chu, C.B., Yan, X., et al. Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Chin Med J (Engl) 117 (2004), 1161–1164.
31. Quadri, P., Fragiacomo, C., Pezzati, R., Zanda, E., Forloni, G., Tettamanti, M., et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 80 (2004), 114–122.
32. Siuda, J., Gorzkowska, A., Patalong-Ogiewa, M., Krzystanek, E., Czech, E., Wiechula, B., et al. From mild cognitive impairment to Alzheimer's disease—influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up. Neurol Neurochir Pol 43 (2009), 321–329.
33. Irizarry, M.C., Gurol, M.E., Raju, S., Diaz-Arrastia, R., Locascio, J.J., Tennis, M., et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 65 (2005), 1402–1408.
34. Kim, J., Park, M.H., Kim, E., Han, C., Jo, S.A., Jo, I., Plasma homocysteine is associated with the risk of mild cognitive impairment in an elderly Korean population. J Nutr 137 (2007), 2093–2097.
35. Nijst, T.Q., Wevers, R.A., Schoonderwaldt, H.C., Hommes, O.R., de Haan, A.F., Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry 53 (1990), 951–954.
36. Popp, J., Lewczuk, P., Linnebank, M., Cvetanovska, G., Smulders, Y., Kolsch, H., et al. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis 18 (2009), 819–828.
37. Hagnelius, N.O., Wahlund, L.O., Nilsson, T.K., CSF/serum folate gradient: physiology and determinants with special reference to dementia. Dement Geriatr Cogn Disord 25 (2008), 516–523.
38. Serot, J.M., Christmann, D., Dubost, T., Bene, M.C., Faure, G.C., CSF-folate levels are decreased in late-onset AD patients. J Neural Transm 108 (2001), 93–99.
39. Smach, M.A., Jacob, N., Golmard, J.L., Charfeddine, B., Lammouchi, T., Ben Othman, L., et al. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer's disease or dementia: a case control study. Eur Neurol 65 (2011), 270–278.
40. Selhub, J., Jacques, P.F., Wilson, P.W., Rush, D., Rosenberg, I.H., Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270 (1993), 2693–2698.
41. Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D'Agostino, R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346 (2002), 476–483.
42. Shen, L., Ji, H.F., Associations between homocysteine, folic acid, vitamin B12 and Alzheimer's disease: insights from meta-analyses. J Alzheimers Dis 46 (2015), 777–790.
43. Trojanowski, J.Q., Vandeerstichele, H., Korecka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6 (2010), 230–238.
44. Shatenstein, B., Kergoat, M.J., Reid, I., Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. J Am Diet Assoc 107 (2007), 2091–2099.
45. McCaddon, A., Davies, G., Hudson, P., Nutritionally independent B12 deficiency and Alzheimer disease. Arch Neurol 57 (2000), 607–608.
46. Astarita, G., Jung, K.M., Berchtold, N.C., Nguyen, V.Q., Gillen, D.L., Head, E., et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One, 5, 2010, e12538.
47. Zhao, R., Diop-Bove, N., Visentin, M., Goldman, I.D., Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 31 (2011), 177–201.
48. Smith, D.E., Smulders, Y.M., Blom, H.J., Popp, J., Jessen, F., Semmler, A., et al. Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and folate, in cerebrospinal fluid. Clin Chem Lab Med 50 (2012), 1641–1647.
49. Goos, J.D., Teunissen, C.E., Veerhuis, R., Verwey, N.A., Barkhof, F., Blankenstein, M.A., et al. Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiol Aging 33 (2012), 1011.e1–1011.e9.
50. van Harten, A.C., Visser, P.J., Pijnenburg, Y.A., Teunissen, C.E., Blankenstein, M.A., Scheltens, P., et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement 9 (2013), 481–487.